[{"orgOrder":0,"company":"NanoViricides","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"URUGUAY","productType":"Undisclosed","year":"2020","type":"Funding","leadProduct":"NV-HHV-101","moa":"","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"NanoViricides","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Cream","sponsorNew":"NanoViricides \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"NanoViricides \/ Undisclosed"},{"orgOrder":0,"company":"NanoViricides","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Not Applicable","leadProduct":"NV-HHV-101","moa":"","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"NanoViricides","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"NanoViricides \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"NanoViricides \/ Not Applicable"},{"orgOrder":0,"company":"NanoViricides","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Not Applicable","leadProduct":"nCoV nanoviricide drug","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"NanoViricides","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"NanoViricides \/ Not Applicable","highestDevelopmentStatusID":"2","companyTruncated":"NanoViricides \/ Not Applicable"},{"orgOrder":0,"company":"NanoViricides","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Not Applicable","leadProduct":"Undisclosed","moa":"ACE2","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"NanoViricides","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"NanoViricides \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"NanoViricides \/ Not Applicable"},{"orgOrder":0,"company":"NanoViricides","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Undisclosed","year":"2020","type":"Not Applicable","leadProduct":"Anti-coronavirus drug","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"NanoViricides","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"NanoViricides \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"NanoViricides \/ Not Applicable"},{"orgOrder":0,"company":"NanoViricides","sponsor":"Maxim Group LLC","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Undisclosed","year":"2020","type":"Public Offering","leadProduct":"NV-HHV-101","moa":"","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"NanoViricides","amount2":0.01,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.01,"dosageForm":"Cream","sponsorNew":"NanoViricides \/ Maxim Group LLC","highestDevelopmentStatusID":"5","companyTruncated":"NanoViricides \/ Maxim Group LLC"},{"orgOrder":0,"company":"NanoViricides","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Undisclosed","year":"2020","type":"Not Applicable","leadProduct":"Undisclosed","moa":"APN","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"NanoViricides","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"NanoViricides \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"NanoViricides \/ Not Applicable"},{"orgOrder":0,"company":"NanoViricides","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Undisclosed","year":"2020","type":"Not Applicable","leadProduct":"Undisclosed","moa":"ACE2","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"NanoViricides","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"NanoViricides \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"NanoViricides \/ Not Applicable"},{"orgOrder":0,"company":"NanoViricides","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Remdesivir","moa":"RdRp","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"NanoViricides","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"NanoViricides \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"NanoViricides \/ Not Applicable"},{"orgOrder":0,"company":"NanoViricides","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Undisclosed","year":"2021","type":"Not Applicable","leadProduct":"NV-CoV-2","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"NanoViricides","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous infusion","sponsorNew":"NanoViricides \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"NanoViricides \/ Not Applicable"},{"orgOrder":0,"company":"NanoViricides","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"NV-Cov-2","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"NanoViricides","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"NanoViricides \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"NanoViricides \/ Not Applicable"},{"orgOrder":0,"company":"NanoViricides","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"NV-CoV-2","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"NanoViricides","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"NanoViricides \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"NanoViricides \/ Not Applicable"},{"orgOrder":0,"company":"NanoViricides","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"NV-Cov-2","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"NanoViricides","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"NanoViricides \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"NanoViricides \/ Not Applicable"},{"orgOrder":0,"company":"NanoViricides","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Tecovirimat","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"NanoViricides","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"NanoViricides \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"NanoViricides \/ Not Applicable"},{"orgOrder":0,"company":"NanoViricides","sponsor":"Karveer Meditech","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Large molecule","year":"2023","type":"Licensing Agreement","leadProduct":"NV-CoV-2","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"NanoViricides","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"NanoViricides \/ Karveer Meditech","highestDevelopmentStatusID":"7","companyTruncated":"NanoViricides \/ Karveer Meditech"},{"orgOrder":0,"company":"NanoViricides","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"NV-387","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"NanoViricides","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Gummies","sponsorNew":"NanoViricides \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"NanoViricides \/ Not Applicable"},{"orgOrder":0,"company":"NanoViricides","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"NV-387","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"NanoViricides","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Gummies","sponsorNew":"NanoViricides \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"NanoViricides \/ Not Applicable"},{"orgOrder":0,"company":"NanoViricides","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"NV-387","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"NanoViricides","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"NanoViricides \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"NanoViricides \/ Not Applicable"},{"orgOrder":0,"company":"NanoViricides","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"NV-387","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"NanoViricides","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Gummies","sponsorNew":"NanoViricides \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"NanoViricides \/ Not Applicable"},{"orgOrder":0,"company":"NanoViricides","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"NV-387","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"NanoViricides","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Gummies","sponsorNew":"NanoViricides \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"NanoViricides \/ Not Applicable"},{"orgOrder":0,"company":"NanoViricides","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"NV-387","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"NanoViricides","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Syrup","sponsorNew":"NanoViricides \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"NanoViricides \/ Not Applicable"},{"orgOrder":0,"company":"NanoViricides","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"NV-387","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"NanoViricides","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Gummies","sponsorNew":"NanoViricides \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"NanoViricides \/ Not Applicable"},{"orgOrder":0,"company":"NanoViricides","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"NV-387","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"NanoViricides","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"NanoViricides \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"NanoViricides \/ Not Applicable"},{"orgOrder":0,"company":"NanoViricides","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"NV-387","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"NanoViricides","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"NanoViricides \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"NanoViricides \/ Not Applicable"},{"orgOrder":0,"company":"NanoViricides","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"NV-387","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"NanoViricides","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"NanoViricides \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"NanoViricides \/ Not Applicable"},{"orgOrder":0,"company":"NanoViricides","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"NV-387","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"NanoViricides","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"NanoViricides \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"NanoViricides \/ Not Applicable"}]
Find Clinical Drug Pipeline Developments & Deals by NanoViricides
Details :
NV-CoV-2 (NV-387) was designed to mimic sulfated proteoglycans, it may possess significant antiviral activity against COVID-19, MPox and Smallpox virus infections.
Details :
NV-387, which has shown strong broad-spectrum antiviral activity not only against multiple coronaviruses, but also against RSV and in animal model.
Details :
NV-CoV-2 (NV-387) was designed to mimic sulfated proteoglycans that a large number of virus families bind to as the first step in infecting a cell. It is being evaluated for Influenza A.
Details :
NV-CoV-2 (NV-387) was designed to mimic sulfated proteoglycans that a large number of virus families bind to as the first step in infecting a cell. It is being evaluated for Influenza A.
Details :
The drug NV-CoV-2 contains the Company's nanoviricide active agent, NV-387, which has shown strong broad-spectrum antiviral activity not only against multiple coronaviruses, but also against RSV and in a model for Smallpox therapeutics.
Details :
NV-CoV-2 (NV-387) was designed to mimic sulfated proteoglycans that a large number of virus families bind to as the first step in infecting a cell. It may possess significant antiviral activity against many other virus families in addition to MPox and Sm...
Details :
NV-CoV-2 (NV-387) was designed to mimic sulfated proteoglycans that a large number of virus families bind to as the first step in infecting a cell. It may possess significant antiviral activity against many other virus families in addition to coronavirus...
Details :
NV-CoV-2 (NV-387) is a first-in-class chemical nanomachine that acts by a novel mechanism of action is re-Infection blocker. which is invetigated for the treatment of covid-19 infection.
Details :
NV-CoV-2 (NV-387) is a first-in-class chemical nanomachine that acts by a novel mechanism of action is re-Infection blocker. which is invetigated for the treatment of covid-19 infection.
Reset All
